FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318309309> ?p ?o ?g. }

• W2318309309 endingPage "246" @default.
• W2318309309 startingPage "240" @default.
• W2318309309 abstract "Zidovudine is a synthetic nucleoside analogue of thymidine with activity against the human immunodeficiency virus type 1 (HIV-1). In patients with HIV infections or the acquired immunodeficiency syndrome (AIDS), zidovudine is a first-line therapy that was shown to reduce morbidity, mortality, and hospitalization. A generic formulation of zidovudine offers the possibility of considerable savings to HIV/AIDS patients in developed and Third World countries. The objective of the current study was to characterize the pharmacokinetic and safety profiles of zidovudine administered as a generic tablet formulation relative to the innovator product.A total of 68 healthy adult volunteers received a 300 mg oral dose of zidovudine as the generic formulation (AVIRO-Z 300 mg tablet, Ranbaxy Laboratories Limited) and as the innovator product (Retrovir tablet, GlaxoSmithKline) in a randomized, 2-way crossover study. Multiple blood samples were collected over 12 hours and plasma concentrations of zidovudine were assayed using an LC/MS/MS method with an analytical range of 5.00 to 2,000 ng/ml. Pharmacokinetic parameters were calculated using non-compartmental methods.Mean plasma concentrations of zidovudine declined in a mono-exponential manner, with mean concentration values falling below the limit of quantitation 12 hours after administration of both formulations. Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively). Ratios of least-squares means and 90% confidence intervals of AUC(0-t) AUC(0-infinity) and C(max) between the 2 formulations were within 80-125%, suggesting that the two tablet formulations displayed similar rate and extent of bioavailability. The oral clearance (CL/F) of zidovudine for the generic and innovator formulations were 2.11 1/h/kg and 2.16 1/h/kg, respectively. For the two formulations, adverse events were similar in nature and frequency.Since the two formulations displayed similar in vivo delivery rate of zidovudine in the bloodstream, the generic tablet formulation of zidovudine developed by Ranbaxy should be equally effective as the innovator product and is expected to produce considerable cost-savings in AIDS patients worldwide." @default.
• W2318309309 created "2016-06-24" @default.
• W2318309309 creator A5000725556 @default.
• W2318309309 creator A5003864929 @default.
• W2318309309 creator A5019278945 @default.
• W2318309309 creator A5023270167 @default.
• W2318309309 creator A5026408371 @default.
• W2318309309 creator A5035876725 @default.
• W2318309309 creator A5040484071 @default.
• W2318309309 creator A5048378439 @default.
• W2318309309 creator A5074541598 @default.
• W2318309309 creator A5084375384 @default.
• W2318309309 creator A5085983812 @default.
• W2318309309 date "2006-05-01" @default.
• W2318309309 modified "2023-09-26" @default.
• W2318309309 title "Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects" @default.
• W2318309309 doi "https://doi.org/10.5414/cpp44240" @default.
• W2318309309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16724579" @default.
• W2318309309 hasPublicationYear "2006" @default.
• W2318309309 type Work @default.
• W2318309309 sameAs 2318309309 @default.
• W2318309309 citedByCount "7" @default.
• W2318309309 countsByYear W23183093092013 @default.
• W2318309309 countsByYear W23183093092014 @default.
• W2318309309 countsByYear W23183093092017 @default.
• W2318309309 crossrefType "journal-article" @default.
• W2318309309 hasAuthorship W2318309309A5000725556 @default.
• W2318309309 hasAuthorship W2318309309A5003864929 @default.
• W2318309309 hasAuthorship W2318309309A5019278945 @default.
• W2318309309 hasAuthorship W2318309309A5023270167 @default.
• W2318309309 hasAuthorship W2318309309A5026408371 @default.
• W2318309309 hasAuthorship W2318309309A5035876725 @default.
• W2318309309 hasAuthorship W2318309309A5040484071 @default.
• W2318309309 hasAuthorship W2318309309A5048378439 @default.
• W2318309309 hasAuthorship W2318309309A5074541598 @default.
• W2318309309 hasAuthorship W2318309309A5084375384 @default.
• W2318309309 hasAuthorship W2318309309A5085983812 @default.
• W2318309309 hasConcept C111919701 @default.
• W2318309309 hasConcept C112705442 @default.
• W2318309309 hasConcept C142724271 @default.
• W2318309309 hasConcept C159047783 @default.
• W2318309309 hasConcept C181389837 @default.
• W2318309309 hasConcept C204787440 @default.
• W2318309309 hasConcept C27081682 @default.
• W2318309309 hasConcept C2776473838 @default.
• W2318309309 hasConcept C2780216070 @default.
• W2318309309 hasConcept C2780727368 @default.
• W2318309309 hasConcept C3013748606 @default.
• W2318309309 hasConcept C34974158 @default.
• W2318309309 hasConcept C41008148 @default.
• W2318309309 hasConcept C42404028 @default.
• W2318309309 hasConcept C71924100 @default.
• W2318309309 hasConcept C76318530 @default.
• W2318309309 hasConcept C87813604 @default.
• W2318309309 hasConcept C98274493 @default.
• W2318309309 hasConceptScore W2318309309C111919701 @default.
• W2318309309 hasConceptScore W2318309309C112705442 @default.
• W2318309309 hasConceptScore W2318309309C142724271 @default.
• W2318309309 hasConceptScore W2318309309C159047783 @default.
• W2318309309 hasConceptScore W2318309309C181389837 @default.
• W2318309309 hasConceptScore W2318309309C204787440 @default.
• W2318309309 hasConceptScore W2318309309C27081682 @default.
• W2318309309 hasConceptScore W2318309309C2776473838 @default.
• W2318309309 hasConceptScore W2318309309C2780216070 @default.
• W2318309309 hasConceptScore W2318309309C2780727368 @default.
• W2318309309 hasConceptScore W2318309309C3013748606 @default.
• W2318309309 hasConceptScore W2318309309C34974158 @default.
• W2318309309 hasConceptScore W2318309309C41008148 @default.
• W2318309309 hasConceptScore W2318309309C42404028 @default.
• W2318309309 hasConceptScore W2318309309C71924100 @default.
• W2318309309 hasConceptScore W2318309309C76318530 @default.
• W2318309309 hasConceptScore W2318309309C87813604 @default.
• W2318309309 hasConceptScore W2318309309C98274493 @default.
• W2318309309 hasIssue "05" @default.
• W2318309309 hasLocation W23183093091 @default.
• W2318309309 hasLocation W23183093092 @default.
• W2318309309 hasOpenAccess W2318309309 @default.
• W2318309309 hasPrimaryLocation W23183093091 @default.
• W2318309309 hasRelatedWork W2353450705 @default.
• W2318309309 hasRelatedWork W2356170336 @default.
• W2318309309 hasRelatedWork W2357220270 @default.
• W2318309309 hasRelatedWork W2360418234 @default.
• W2318309309 hasRelatedWork W2373452970 @default.
• W2318309309 hasRelatedWork W2374069256 @default.
• W2318309309 hasRelatedWork W2380091905 @default.
• W2318309309 hasRelatedWork W2380433639 @default.
• W2318309309 hasRelatedWork W2391752688 @default.
• W2318309309 hasRelatedWork W2415829651 @default.
• W2318309309 hasVolume "44" @default.
• W2318309309 isParatext "false" @default.
• W2318309309 isRetracted "false" @default.
• W2318309309 magId "2318309309" @default.
• W2318309309 workType "article" @default.